Quick Answer
AYTU BIOPHARMA, INC reported Revenue From Contract With Customer Excluding Assessed Tax of $66.38 million for the year ending 2025.
- AYTU BIOPHARMA, INC showed an increase of +1.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from AYTU BIOPHARMA, INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $13.52 million | Q4 2020: $15.15 million | Q1 2021: $13.48 million | Q3 2021: $21.90 million | Q4 2021: $23.13 million | Q1 2022: $24.20 million | Q3 2022: $27.66 million | Q4 2022: $26.28 million | Q1 2023: $22.73 million | Q3 2023: $17.82 million | Q4 2023: $18.75 million | Q1 2024: $14.03 million | Q3 2024: $16.57 million | Q4 2024: $16.22 million | Q1 2025: $18.45 million | Q3 2025: $13.89 million | Q4 2025: $15.17 million.
- Over the full 6 years of available data (2020 to 2025), AYTU BIOPHARMA, INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 140.2%.
- Historical annual values: Fiscal year 2025: $66.38 million | Fiscal year 2024: $65.18 million | Fiscal year 2023: $107.40 million | Fiscal year 2022: $96.67 million | Fiscal year 2021: $65.63 million | Fiscal year 2020: $27.63 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: